Healthcare resource utilisation and costs among patients with versus without Huntington’s disease in the US population
Objective: Compare the marginal healthcare resource utilisation (HRU) and costs between US patients with Huntington’s disease (HD) and non-HD controls. Background: HD is a genetic,…Deutetrabenazine for Huntington’s disease chorea—A Single Center’s Experience
Objective: To evaluate real-world use and outcomes with deutetrabenazine for Huntington’s disease. Background: Grade A evidence for Huntington’s disease chorea treatment includes tetrabenazine and deutetrabenazine.…Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease
Objective: To evaluate the safety and tolerability of deutetrabenazine >48 mg/d compared to ≤48 mg/d to treat Huntington’s disease (HD)–associated chorea in ARC-HD. Background: In…VMAT 2 inhibitor and Antipsychotic use in Individuals with Huntington’s Disease
Objective: To retrospectively investigate whether the concomitant use of VMAT2 inhibitors and antipsychotics in individuals with Huntington's disease (HD) is associated with an increased occurrence…Cytokines and Brain Specific Antibodies in Experimental Cellular and Molecular Treatment of Huntington’s Diseases
Objective: Huntington’s Disease (HD) is a severe neurodegenerative disorder main pathogenic factor is CAG repeats in a suffered patients genome. Experimental therapy on the model…A longitudinal PET study to assess the state of microglia activation in a Phase 2 study of Laquinimod as a treatment for Huntington’s disease (LEGATO-HD)
Objective: To assess in vivo in Huntington’s disease (HD) changes in microglia activation state, due to treatment with laquinimod, as reflected by changes in 11C-PBR28…Biological and Clinical Manifestations of Huntington’s disease in Gene Carriers Very Far from Predicted Onset: The Young Adult Study
Objective: To perform a deep phenotyping of a Huntington’s Disease (HD) cohort further from onset than previously studied to establish when disease related markers first…A Rare Disease with Atypical Clinical And Imaging Findings: Anti Lgi-1 Encephalitis
Objective: We present a case that will raise awareness about the disease with atypical clinical and rich imaging findings that has benefited greatly from intensive…Hyperpolarization of the subthalamic nucleus alleviates hyperkinetic movement disorders
Objective: We test the hypothesis of modulating subthalamic neuronal firing pattern via injection of hyperpolarizing current as an effective treatment for hyperkinetic movement disorders. Background:…Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington’s Disease or Tardive Dyskinesia
Objective: To evaluate real-world treatment patterns and adherence to deutetrabenazine (DTBZ) in patients with Huntington’s disease (HD) or tardive dyskinesia (TD). Background: DTBZ is a…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- Next Page »